AP129A - Expression of retrovirus gag protein eukaryotic cells - Google Patents
Expression of retrovirus gag protein eukaryotic cells Download PDFInfo
- Publication number
- AP129A AP129A APAP/P/1989/000126A AP8900126A AP129A AP 129 A AP129 A AP 129A AP 8900126 A AP8900126 A AP 8900126A AP 129 A AP129 A AP 129A
- Authority
- AP
- ARIPO
- Prior art keywords
- cells
- gag
- precursor protein
- recombinant
- dna molecule
- Prior art date
Links
- 210000003527 eukaryotic cell Anatomy 0.000 title claims abstract description 10
- 241001430294 unidentified retrovirus Species 0.000 title abstract description 6
- 101710177291 Gag polyprotein Proteins 0.000 title description 19
- 101710125418 Major capsid protein Proteins 0.000 title description 18
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 96
- 239000002243 precursor Substances 0.000 claims abstract description 93
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 84
- 108020004511 Recombinant DNA Proteins 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 17
- 210000004027 cell Anatomy 0.000 claims description 106
- 239000002245 particle Substances 0.000 claims description 88
- 241000700605 Viruses Species 0.000 claims description 47
- 102000053602 DNA Human genes 0.000 claims description 27
- 108091026890 Coding region Proteins 0.000 claims description 23
- 230000001105 regulatory effect Effects 0.000 claims description 19
- 206010061598 Immunodeficiency Diseases 0.000 claims description 17
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 17
- 239000003636 conditioned culture medium Substances 0.000 claims description 17
- 230000007813 immunodeficiency Effects 0.000 claims description 17
- 229960005486 vaccine Drugs 0.000 claims description 17
- 210000004962 mammalian cell Anatomy 0.000 claims description 15
- 241000238631 Hexapoda Species 0.000 claims description 14
- 208000015181 infectious disease Diseases 0.000 claims description 14
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 13
- 241000255777 Lepidoptera Species 0.000 claims description 12
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 claims description 10
- 230000003612 virological effect Effects 0.000 claims description 10
- 230000002163 immunogen Effects 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000029302 virus maturation Effects 0.000 claims description 5
- 241000256248 Spodoptera Species 0.000 claims description 3
- 210000001124 body fluid Anatomy 0.000 claims description 3
- 108020005065 3' Flanking Region Proteins 0.000 claims description 2
- 108020005029 5' Flanking Region Proteins 0.000 claims description 2
- 101100327917 Caenorhabditis elegans chup-1 gene Proteins 0.000 claims description 2
- 241000287828 Gallus gallus Species 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 101150012394 PHO5 gene Proteins 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 230000029812 viral genome replication Effects 0.000 claims description 2
- 210000005253 yeast cell Anatomy 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims 4
- 101100290380 Caenorhabditis elegans cel-1 gene Proteins 0.000 claims 2
- 241000700618 Vaccinia virus Species 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 108010021809 Alcohol dehydrogenase Proteins 0.000 claims 1
- 101100480861 Caldanaerobacter subterraneus subsp. tengcongensis (strain DSM 15242 / JCM 11007 / NBRC 100824 / MB4) tdh gene Proteins 0.000 claims 1
- 101100447466 Candida albicans (strain WO-1) TDH1 gene Proteins 0.000 claims 1
- 101001046426 Homo sapiens cGMP-dependent protein kinase 1 Proteins 0.000 claims 1
- 101001000154 Schistosoma mansoni Phosphoglycerate kinase Proteins 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 101150088047 tdh3 gene Proteins 0.000 claims 1
- 210000003501 vero cell Anatomy 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 58
- 241000725303 Human immunodeficiency virus Species 0.000 description 37
- 101710205625 Capsid protein p24 Proteins 0.000 description 31
- 101710177166 Phosphoprotein Proteins 0.000 description 31
- 101710149279 Small delta antigen Proteins 0.000 description 31
- 102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 31
- 102100036352 Protein disulfide-isomerase Human genes 0.000 description 27
- 239000012634 fragment Substances 0.000 description 24
- 241000701447 unidentified baculovirus Species 0.000 description 24
- BYXHQQCXAJARLQ-ZLUOBGJFSA-N Ala-Ala-Ala Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O BYXHQQCXAJARLQ-ZLUOBGJFSA-N 0.000 description 21
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 20
- 239000000427 antigen Substances 0.000 description 17
- 108091007433 antigens Proteins 0.000 description 17
- 102000036639 antigens Human genes 0.000 description 17
- 241000713311 Simian immunodeficiency virus Species 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 15
- 239000013598 vector Substances 0.000 description 15
- 238000003556 assay Methods 0.000 description 13
- 238000001262 western blot Methods 0.000 description 13
- 210000000170 cell membrane Anatomy 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 208000030507 AIDS Diseases 0.000 description 9
- 230000034303 cell budding Effects 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 101710182846 Polyhedrin Proteins 0.000 description 8
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 6
- 239000004471 Glycine Substances 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 6
- 239000004365 Protease Substances 0.000 description 6
- 229920004890 Triton X-100 Polymers 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 238000001493 electron microscopy Methods 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 238000005755 formation reaction Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- -1 pi7 Proteins 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 102100034349 Integrase Human genes 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 239000007771 core particle Substances 0.000 description 5
- 108700004026 gag Genes Proteins 0.000 description 5
- 101150098622 gag gene Proteins 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 230000007498 myristoylation Effects 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 4
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 4
- 101710132601 Capsid protein Proteins 0.000 description 4
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 4
- 235000021360 Myristic acid Nutrition 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000003599 detergent Substances 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 238000005199 ultracentrifugation Methods 0.000 description 4
- 241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 description 4
- 108010039627 Aprotinin Proteins 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- 101710091045 Envelope protein Proteins 0.000 description 3
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 3
- 101710188315 Protein X Proteins 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 229960004405 aprotinin Drugs 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 239000013599 cloning vector Substances 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 239000007857 degradation product Substances 0.000 description 3
- 230000037433 frameshift Effects 0.000 description 3
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 238000004626 scanning electron microscopy Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 241001529453 unidentified herpesvirus Species 0.000 description 3
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 2
- OLVCTPPSXNRGKV-GUBZILKMSA-N Ala-Pro-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 OLVCTPPSXNRGKV-GUBZILKMSA-N 0.000 description 2
- KMFPQTITXUKJOV-DCAQKATOSA-N Arg-Ser-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O KMFPQTITXUKJOV-DCAQKATOSA-N 0.000 description 2
- 241001203868 Autographa californica Species 0.000 description 2
- 241000255789 Bombyx mori Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- SWDNPSMMEWRNOH-HJGDQZAQSA-N Glu-Pro-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O SWDNPSMMEWRNOH-HJGDQZAQSA-N 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 239000000232 Lipid Bilayer Substances 0.000 description 2
- 102000003792 Metallothionein Human genes 0.000 description 2
- 108090000157 Metallothionein Proteins 0.000 description 2
- 241000713862 Moloney murine sarcoma virus Species 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 241000712907 Retroviridae Species 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- NRCJWSGXMAPYQX-LPEHRKFASA-N Ser-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)N)C(=O)O NRCJWSGXMAPYQX-LPEHRKFASA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 241000255993 Trichoplusia ni Species 0.000 description 2
- 101150050575 URA3 gene Proteins 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 101150047047 gag-pol gene Proteins 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 108010073101 phenylalanylleucine Proteins 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 108700004029 pol Genes Proteins 0.000 description 2
- 101150088264 pol gene Proteins 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 108010077112 prolyl-proline Proteins 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 101150090724 3 gene Proteins 0.000 description 1
- HFGHRUCCKVYFKL-UHFFFAOYSA-N 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5h-pyrimido[5,4-b]indole Chemical compound C1=C2NC=3C(OCC)=NC(N4CCNCC4)=NC=3C2=CC=C1C1=CC=NC=C1 HFGHRUCCKVYFKL-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 241000714195 Aids-associated retrovirus Species 0.000 description 1
- YLTKNGYYPIWKHZ-ACZMJKKPSA-N Ala-Ala-Glu Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O YLTKNGYYPIWKHZ-ACZMJKKPSA-N 0.000 description 1
- VBDMWOKJZDCFJM-FXQIFTODSA-N Ala-Ala-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)N VBDMWOKJZDCFJM-FXQIFTODSA-N 0.000 description 1
- JBVSSSZFNTXJDX-YTLHQDLWSA-N Ala-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)N JBVSSSZFNTXJDX-YTLHQDLWSA-N 0.000 description 1
- CCUAQNUWXLYFRA-IMJSIDKUSA-N Ala-Asn Chemical compound C[C@H]([NH3+])C(=O)N[C@H](C([O-])=O)CC(N)=O CCUAQNUWXLYFRA-IMJSIDKUSA-N 0.000 description 1
- MQIGTEQXYCRLGK-BQBZGAKWSA-N Ala-Gly-Pro Chemical compound C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O MQIGTEQXYCRLGK-BQBZGAKWSA-N 0.000 description 1
- OBVSBEYOMDWLRJ-BFHQHQDPSA-N Ala-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N OBVSBEYOMDWLRJ-BFHQHQDPSA-N 0.000 description 1
- AWNAEZICPNGAJK-FXQIFTODSA-N Ala-Met-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(O)=O AWNAEZICPNGAJK-FXQIFTODSA-N 0.000 description 1
- YCRAFFCYWOUEOF-DLOVCJGASA-N Ala-Phe-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 YCRAFFCYWOUEOF-DLOVCJGASA-N 0.000 description 1
- IPWKGIFRRBGCJO-IMJSIDKUSA-N Ala-Ser Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O IPWKGIFRRBGCJO-IMJSIDKUSA-N 0.000 description 1
- VJVQKGYHIZPSNS-FXQIFTODSA-N Ala-Ser-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N VJVQKGYHIZPSNS-FXQIFTODSA-N 0.000 description 1
- XPBVBZPVNFIHOA-UVBJJODRSA-N Ala-Trp-Val Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@H](C)N)=CNC2=C1 XPBVBZPVNFIHOA-UVBJJODRSA-N 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- VKKYFICVTYKFIO-CIUDSAMLSA-N Arg-Ala-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N VKKYFICVTYKFIO-CIUDSAMLSA-N 0.000 description 1
- DBKNLHKEVPZVQC-LPEHRKFASA-N Arg-Ala-Pro Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(O)=O DBKNLHKEVPZVQC-LPEHRKFASA-N 0.000 description 1
- RWWPBOUMKFBHAL-FXQIFTODSA-N Arg-Asn-Cys Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(O)=O RWWPBOUMKFBHAL-FXQIFTODSA-N 0.000 description 1
- HPSVTWMFWCHKFN-GARJFASQSA-N Arg-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O HPSVTWMFWCHKFN-GARJFASQSA-N 0.000 description 1
- PNIGSVZJNVUVJA-BQBZGAKWSA-N Arg-Gly-Asn Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O PNIGSVZJNVUVJA-BQBZGAKWSA-N 0.000 description 1
- WVNFNPGXYADPPO-BQBZGAKWSA-N Arg-Gly-Ser Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O WVNFNPGXYADPPO-BQBZGAKWSA-N 0.000 description 1
- LVMUGODRNHFGRA-AVGNSLFASA-N Arg-Leu-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O LVMUGODRNHFGRA-AVGNSLFASA-N 0.000 description 1
- BTJVOUQWFXABOI-IHRRRGAJSA-N Arg-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCNC(N)=N BTJVOUQWFXABOI-IHRRRGAJSA-N 0.000 description 1
- MTYLORHAQXVQOW-AVGNSLFASA-N Arg-Lys-Met Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(O)=O MTYLORHAQXVQOW-AVGNSLFASA-N 0.000 description 1
- CZUHPNLXLWMYMG-UBHSHLNASA-N Arg-Phe-Ala Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CC=CC=C1 CZUHPNLXLWMYMG-UBHSHLNASA-N 0.000 description 1
- SWLOHUMCUDRTCL-ZLUOBGJFSA-N Asn-Ala-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N SWLOHUMCUDRTCL-ZLUOBGJFSA-N 0.000 description 1
- BZMWJLLUAKSIMH-FXQIFTODSA-N Asn-Glu-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O BZMWJLLUAKSIMH-FXQIFTODSA-N 0.000 description 1
- COWITDLVHMZSIW-CIUDSAMLSA-N Asn-Lys-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O COWITDLVHMZSIW-CIUDSAMLSA-N 0.000 description 1
- BCADFFUQHIMQAA-KKHAAJSZSA-N Asn-Thr-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O BCADFFUQHIMQAA-KKHAAJSZSA-N 0.000 description 1
- FYRVDDJMNISIKJ-UWVGGRQHSA-N Asn-Tyr Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 FYRVDDJMNISIKJ-UWVGGRQHSA-N 0.000 description 1
- MRQQMVZUHXUPEV-IHRRRGAJSA-N Asp-Arg-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O MRQQMVZUHXUPEV-IHRRRGAJSA-N 0.000 description 1
- XYBJLTKSGFBLCS-QXEWZRGKSA-N Asp-Arg-Val Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CC(O)=O XYBJLTKSGFBLCS-QXEWZRGKSA-N 0.000 description 1
- CLUMZOKVGUWUFD-CIUDSAMLSA-N Asp-Leu-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O CLUMZOKVGUWUFD-CIUDSAMLSA-N 0.000 description 1
- FOXXZZGDIAQPQI-XKNYDFJKSA-N Asp-Pro-Ser-Ser Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O FOXXZZGDIAQPQI-XKNYDFJKSA-N 0.000 description 1
- JJQGZGOEDSSHTE-FOHZUACHSA-N Asp-Thr-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O JJQGZGOEDSSHTE-FOHZUACHSA-N 0.000 description 1
- BYLPQJAWXJWUCJ-YDHLFZDLSA-N Asp-Tyr-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O BYLPQJAWXJWUCJ-YDHLFZDLSA-N 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 101100422644 Caenorhabditis elegans syx-5 gene Proteins 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- DZSICRGTVPDCRN-YUMQZZPRSA-N Cys-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CS)N DZSICRGTVPDCRN-YUMQZZPRSA-N 0.000 description 1
- JLZCAZJGWNRXCI-XKBZYTNZSA-N Cys-Thr-Glu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O JLZCAZJGWNRXCI-XKBZYTNZSA-N 0.000 description 1
- PXEGEYISOXISDV-XIRDDKMYSA-N Cys-Trp-Lys Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@@H](N)CS)=CNC2=C1 PXEGEYISOXISDV-XIRDDKMYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 241000255597 Drosophila hydei Species 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241001200922 Gagata Species 0.000 description 1
- 241000255896 Galleria mellonella Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- BUZMZDDKFCSKOT-CIUDSAMLSA-N Glu-Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O BUZMZDDKFCSKOT-CIUDSAMLSA-N 0.000 description 1
- MUSGDMDGNGXULI-DCAQKATOSA-N Glu-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O MUSGDMDGNGXULI-DCAQKATOSA-N 0.000 description 1
- LGYZYFFDELZWRS-DCAQKATOSA-N Glu-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O LGYZYFFDELZWRS-DCAQKATOSA-N 0.000 description 1
- IQACOVZVOMVILH-FXQIFTODSA-N Glu-Glu-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O IQACOVZVOMVILH-FXQIFTODSA-N 0.000 description 1
- LYCDZGLXQBPNQU-WDSKDSINSA-N Glu-Gly-Cys Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CS)C(O)=O LYCDZGLXQBPNQU-WDSKDSINSA-N 0.000 description 1
- IRXNJYPKBVERCW-DCAQKATOSA-N Glu-Leu-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O IRXNJYPKBVERCW-DCAQKATOSA-N 0.000 description 1
- YBTCBQBIJKGSJP-BQBZGAKWSA-N Glu-Pro Chemical compound OC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O YBTCBQBIJKGSJP-BQBZGAKWSA-N 0.000 description 1
- YQAQQKPWFOBSMU-WDCWCFNPSA-N Glu-Thr-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O YQAQQKPWFOBSMU-WDCWCFNPSA-N 0.000 description 1
- MXJYXYDREQWUMS-XKBZYTNZSA-N Glu-Thr-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O MXJYXYDREQWUMS-XKBZYTNZSA-N 0.000 description 1
- 108010033128 Glucan Endo-1,3-beta-D-Glucosidase Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- JLXVRFDTDUGQEE-YFKPBYRVSA-N Gly-Arg Chemical compound NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N JLXVRFDTDUGQEE-YFKPBYRVSA-N 0.000 description 1
- UHPAZODVFFYEEL-QWRGUYRKSA-N Gly-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN UHPAZODVFFYEEL-QWRGUYRKSA-N 0.000 description 1
- VEPBEGNDJYANCF-QWRGUYRKSA-N Gly-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCCN VEPBEGNDJYANCF-QWRGUYRKSA-N 0.000 description 1
- NSVOVKWEKGEOQB-LURJTMIESA-N Gly-Pro-Gly Chemical compound NCC(=O)N1CCC[C@H]1C(=O)NCC(O)=O NSVOVKWEKGEOQB-LURJTMIESA-N 0.000 description 1
- RJVZMGQMJOQIAX-GJZGRUSLSA-N Gly-Trp-Met Chemical compound [H]NCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCSC)C(O)=O RJVZMGQMJOQIAX-GJZGRUSLSA-N 0.000 description 1
- SYOJVRNQCXYEOV-XVKPBYJWSA-N Gly-Val-Glu Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SYOJVRNQCXYEOV-XVKPBYJWSA-N 0.000 description 1
- RYAOJUMWLWUGNW-QMMMGPOBSA-N Gly-Val-Gly Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O RYAOJUMWLWUGNW-QMMMGPOBSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 108010010369 HIV Protease Proteins 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 101100246753 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) pyrF gene Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 241000255967 Helicoverpa zea Species 0.000 description 1
- PGRPSOUCWRBWKZ-DLOVCJGASA-N His-Lys-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CN=CN1 PGRPSOUCWRBWKZ-DLOVCJGASA-N 0.000 description 1
- VIJMRAIWYWRXSR-CIUDSAMLSA-N His-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CN=CN1 VIJMRAIWYWRXSR-CIUDSAMLSA-N 0.000 description 1
- BRQKGRLDDDQWQJ-MBLNEYKQSA-N His-Thr-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O BRQKGRLDDDQWQJ-MBLNEYKQSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 241000829111 Human polyomavirus 1 Species 0.000 description 1
- 241001135958 Human type D retrovirus Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- IBMVEYRWAWIOTN-UHFFFAOYSA-N L-Leucyl-L-Arginyl-L-Proline Natural products CC(C)CC(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(O)=O IBMVEYRWAWIOTN-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- UGTHTQWIQKEDEH-BQBZGAKWSA-N L-alanyl-L-prolylglycine zwitterion Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UGTHTQWIQKEDEH-BQBZGAKWSA-N 0.000 description 1
- LHSGPCFBGJHPCY-UHFFFAOYSA-N L-leucine-L-tyrosine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- LZDNBBYBDGBADK-UHFFFAOYSA-N L-valyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C(C)C)C(O)=O)=CNC2=C1 LZDNBBYBDGBADK-UHFFFAOYSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- CQQGCWPXDHTTNF-GUBZILKMSA-N Leu-Ala-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O CQQGCWPXDHTTNF-GUBZILKMSA-N 0.000 description 1
- YKNBJXOJTURHCU-DCAQKATOSA-N Leu-Asp-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N YKNBJXOJTURHCU-DCAQKATOSA-N 0.000 description 1
- MYGQXVYRZMKRDB-SRVKXCTJSA-N Leu-Asp-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN MYGQXVYRZMKRDB-SRVKXCTJSA-N 0.000 description 1
- WIDZHJTYKYBLSR-DCAQKATOSA-N Leu-Glu-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O WIDZHJTYKYBLSR-DCAQKATOSA-N 0.000 description 1
- LESXFEZIFXFIQR-LURJTMIESA-N Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(O)=O LESXFEZIFXFIQR-LURJTMIESA-N 0.000 description 1
- HYIFFZAQXPUEAU-QWRGUYRKSA-N Leu-Gly-Leu Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(C)C HYIFFZAQXPUEAU-QWRGUYRKSA-N 0.000 description 1
- YFBBUHJJUXXZOF-UWVGGRQHSA-N Leu-Gly-Pro Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O YFBBUHJJUXXZOF-UWVGGRQHSA-N 0.000 description 1
- ZRHDPZAAWLXXIR-SRVKXCTJSA-N Leu-Lys-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O ZRHDPZAAWLXXIR-SRVKXCTJSA-N 0.000 description 1
- REPBGZHJKYWFMJ-KKUMJFAQSA-N Leu-Lys-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N REPBGZHJKYWFMJ-KKUMJFAQSA-N 0.000 description 1
- LHSGPCFBGJHPCY-STQMWFEESA-N Leu-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-STQMWFEESA-N 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- CIOWSLJGLSUOME-BQBZGAKWSA-N Lys-Asp Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O CIOWSLJGLSUOME-BQBZGAKWSA-N 0.000 description 1
- GCMWRRQAKQXDED-IUCAKERBSA-N Lys-Glu-Gly Chemical compound [NH3+]CCCC[C@H]([NH3+])C(=O)N[C@@H](CCC([O-])=O)C(=O)NCC([O-])=O GCMWRRQAKQXDED-IUCAKERBSA-N 0.000 description 1
- DCRWPTBMWMGADO-AVGNSLFASA-N Lys-Glu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O DCRWPTBMWMGADO-AVGNSLFASA-N 0.000 description 1
- XOQMURBBIXRRCR-SRVKXCTJSA-N Lys-Lys-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN XOQMURBBIXRRCR-SRVKXCTJSA-N 0.000 description 1
- ZOKVLMBYDSIDKG-CSMHCCOUSA-N Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN ZOKVLMBYDSIDKG-CSMHCCOUSA-N 0.000 description 1
- WINFHLHJTRGLCV-BZSNNMDCSA-N Lys-Tyr-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CC=C(O)C=C1 WINFHLHJTRGLCV-BZSNNMDCSA-N 0.000 description 1
- IKXQOBUBZSOWDY-AVGNSLFASA-N Lys-Val-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CCCCN)N IKXQOBUBZSOWDY-AVGNSLFASA-N 0.000 description 1
- 241000255908 Manduca sexta Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- KMSMNUFBNCHMII-IHRRRGAJSA-N Met-Leu-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCCN KMSMNUFBNCHMII-IHRRRGAJSA-N 0.000 description 1
- YYEIFXZOBZVDPH-DCAQKATOSA-N Met-Lys-Asp Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O YYEIFXZOBZVDPH-DCAQKATOSA-N 0.000 description 1
- ZYTPOUNUXRBYGW-YUMQZZPRSA-N Met-Met Chemical compound CSCC[C@H]([NH3+])C(=O)N[C@H](C([O-])=O)CCSC ZYTPOUNUXRBYGW-YUMQZZPRSA-N 0.000 description 1
- ILKCLLLOGPDNIP-RCWTZXSCSA-N Met-Met-Thr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ILKCLLLOGPDNIP-RCWTZXSCSA-N 0.000 description 1
- BAQCROVBDNBEEB-UBYUBLNFSA-N Metrizamide Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)N[C@@H]2[C@H]([C@H](O)[C@@H](CO)OC2O)O)=C1I BAQCROVBDNBEEB-UBYUBLNFSA-N 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 101100202339 Mus musculus Slc6a13 gene Proteins 0.000 description 1
- XZFYRXDAULDNFX-UHFFFAOYSA-N N-L-cysteinyl-L-phenylalanine Natural products SCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XZFYRXDAULDNFX-UHFFFAOYSA-N 0.000 description 1
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 108010066427 N-valyltryptophan Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- JEGFCFLCRSJCMA-IHRRRGAJSA-N Phe-Arg-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)O)N JEGFCFLCRSJCMA-IHRRRGAJSA-N 0.000 description 1
- UUWCIPUVJJIEEP-SRVKXCTJSA-N Phe-Asn-Cys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N UUWCIPUVJJIEEP-SRVKXCTJSA-N 0.000 description 1
- WPTYDQPGBMDUBI-QWRGUYRKSA-N Phe-Gly-Asn Chemical compound N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O WPTYDQPGBMDUBI-QWRGUYRKSA-N 0.000 description 1
- SMFGCTXUBWEPKM-KBPBESRZSA-N Phe-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 SMFGCTXUBWEPKM-KBPBESRZSA-N 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- VPEVBAUSTBWQHN-NHCYSSNCSA-N Pro-Glu-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O VPEVBAUSTBWQHN-NHCYSSNCSA-N 0.000 description 1
- UUHXBJHVTVGSKM-BQBZGAKWSA-N Pro-Gly-Asn Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O UUHXBJHVTVGSKM-BQBZGAKWSA-N 0.000 description 1
- XQPHBAKJJJZOBX-SRVKXCTJSA-N Pro-Lys-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O XQPHBAKJJJZOBX-SRVKXCTJSA-N 0.000 description 1
- LGMBKOAPPTYKLC-JYJNAYRXSA-N Pro-Phe-Arg Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(O)=O)NC(=O)[C@H]1NCCC1)C1=CC=CC=C1 LGMBKOAPPTYKLC-JYJNAYRXSA-N 0.000 description 1
- RWCOTTLHDJWHRS-YUMQZZPRSA-N Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 RWCOTTLHDJWHRS-YUMQZZPRSA-N 0.000 description 1
- LNICFEXCAHIJOR-DCAQKATOSA-N Pro-Ser-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O LNICFEXCAHIJOR-DCAQKATOSA-N 0.000 description 1
- FUOGXAQMNJMBFG-WPRPVWTQSA-N Pro-Val-Gly Chemical compound OC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 FUOGXAQMNJMBFG-WPRPVWTQSA-N 0.000 description 1
- DGDCSVGVWWAJRS-AVGNSLFASA-N Pro-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@@H]2CCCN2 DGDCSVGVWWAJRS-AVGNSLFASA-N 0.000 description 1
- VRDIULHPQTYCLN-UHFFFAOYSA-N Prothionamide Chemical group CCCC1=CC(C(N)=S)=CC=N1 VRDIULHPQTYCLN-UHFFFAOYSA-N 0.000 description 1
- 241001456341 Rachiplusia ou Species 0.000 description 1
- 101100202330 Rattus norvegicus Slc6a11 gene Proteins 0.000 description 1
- 208000005074 Retroviridae Infections Diseases 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000235346 Schizosaccharomyces Species 0.000 description 1
- NUEHQDHDLDXCRU-GUBZILKMSA-N Ser-Pro-Arg Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O NUEHQDHDLDXCRU-GUBZILKMSA-N 0.000 description 1
- NADLKBTYNKUJEP-KATARQTJSA-N Ser-Thr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O NADLKBTYNKUJEP-KATARQTJSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 101150033766 Syn3 gene Proteins 0.000 description 1
- 241000473945 Theria <moth genus> Species 0.000 description 1
- CAJFZCICSVBOJK-SHGPDSBTSA-N Thr-Ala-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAJFZCICSVBOJK-SHGPDSBTSA-N 0.000 description 1
- DJDSEDOKJTZBAR-ZDLURKLDSA-N Thr-Gly-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O DJDSEDOKJTZBAR-ZDLURKLDSA-N 0.000 description 1
- IMDMLDSVUSMAEJ-HJGDQZAQSA-N Thr-Leu-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O IMDMLDSVUSMAEJ-HJGDQZAQSA-N 0.000 description 1
- SCSVNSNWUTYSFO-WDCWCFNPSA-N Thr-Lys-Glu Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O SCSVNSNWUTYSFO-WDCWCFNPSA-N 0.000 description 1
- XNTVWRJTUIOGQO-RHYQMDGZSA-N Thr-Met-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O XNTVWRJTUIOGQO-RHYQMDGZSA-N 0.000 description 1
- AHERARIZBPOMNU-KATARQTJSA-N Thr-Ser-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O AHERARIZBPOMNU-KATARQTJSA-N 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- MICFJCRQBFSKPA-UMPQAUOISA-N Trp-Met-Thr Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)=CNC2=C1 MICFJCRQBFSKPA-UMPQAUOISA-N 0.000 description 1
- OJKVFAWXPGCJMF-BPUTZDHNSA-N Trp-Pro-Ser Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC2=CNC3=CC=CC=C32)N)C(=O)N[C@@H](CO)C(=O)O OJKVFAWXPGCJMF-BPUTZDHNSA-N 0.000 description 1
- ZNFPUOSTMUMUDR-JRQIVUDYSA-N Tyr-Asn-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZNFPUOSTMUMUDR-JRQIVUDYSA-N 0.000 description 1
- WOAQYWUEUYMVGK-ULQDDVLXSA-N Tyr-Lys-Arg Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O WOAQYWUEUYMVGK-ULQDDVLXSA-N 0.000 description 1
- SINRIKQYQJRGDQ-MEYUZBJRSA-N Tyr-Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 SINRIKQYQJRGDQ-MEYUZBJRSA-N 0.000 description 1
- BIWVVOHTKDLRMP-ULQDDVLXSA-N Tyr-Pro-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O BIWVVOHTKDLRMP-ULQDDVLXSA-N 0.000 description 1
- SYFHQHYTNCQCCN-MELADBBJSA-N Tyr-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)O SYFHQHYTNCQCCN-MELADBBJSA-N 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- SLLKXDSRVAOREO-KZVJFYERSA-N Val-Ala-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)N)O SLLKXDSRVAOREO-KZVJFYERSA-N 0.000 description 1
- IDKGBVZGNTYYCC-QXEWZRGKSA-N Val-Asn-Pro Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(O)=O IDKGBVZGNTYYCC-QXEWZRGKSA-N 0.000 description 1
- XXWBHOWRARMUOC-NHCYSSNCSA-N Val-Lys-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)O)N XXWBHOWRARMUOC-NHCYSSNCSA-N 0.000 description 1
- SJLVYVZBFDTRCG-DCAQKATOSA-N Val-Lys-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)O)N SJLVYVZBFDTRCG-DCAQKATOSA-N 0.000 description 1
- PQSNETRGCRUOGP-KKHAAJSZSA-N Val-Thr-Asn Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(N)=O PQSNETRGCRUOGP-KKHAAJSZSA-N 0.000 description 1
- LZDNBBYBDGBADK-KBPBESRZSA-N Val-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)C(C)C)C(O)=O)=CNC2=C1 LZDNBBYBDGBADK-KBPBESRZSA-N 0.000 description 1
- STTYIMSDIYISRG-UHFFFAOYSA-N Valyl-Serine Chemical compound CC(C)C(N)C(=O)NC(CO)C(O)=O STTYIMSDIYISRG-UHFFFAOYSA-N 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- YHGREDQDBYVEOS-UHFFFAOYSA-N [acetyloxy-[2-(diacetyloxyamino)ethyl]amino] acetate Chemical compound CC(=O)ON(OC(C)=O)CCN(OC(C)=O)OC(C)=O YHGREDQDBYVEOS-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 108010013835 arginine glutamate Proteins 0.000 description 1
- 108010077245 asparaginyl-proline Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 108010016616 cysteinylglycine Proteins 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 108010051307 glycyl-glycyl-proline Proteins 0.000 description 1
- 108010038983 glycyl-histidyl-lysine Proteins 0.000 description 1
- 108010008671 glycyl-tryptophyl-methionine Proteins 0.000 description 1
- 108010020688 glycylhistidine Proteins 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000000087 hemolymph Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 108010040030 histidinoalanine Proteins 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 108010012058 leucyltyrosine Proteins 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 108010003700 lysyl aspartic acid Proteins 0.000 description 1
- 108010009298 lysylglutamic acid Proteins 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 108010054155 lysyllysine Proteins 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 108010085203 methionylmethionine Proteins 0.000 description 1
- 229960000554 metrizamide Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108010004914 prolylarginine Proteins 0.000 description 1
- 108010070643 prolylglutamic acid Proteins 0.000 description 1
- 108010029020 prolylglycine Proteins 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000164 protein isolation Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 108010031491 threonyl-lysyl-glutamic acid Proteins 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000024275 uncoating of virus Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000007502 viral entry Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 230000010464 virion assembly Effects 0.000 description 1
- 230000021887 virion transport Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20227188A | 1988-06-03 | 1988-06-03 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP8900126A0 AP8900126A0 (en) | 1989-07-31 |
| AP129A true AP129A (en) | 1991-04-17 |
Family
ID=22749175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/1989/000126A AP129A (en) | 1988-06-03 | 1989-05-22 | Expression of retrovirus gag protein eukaryotic cells |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0345242A3 (fr) |
| AP (1) | AP129A (fr) |
| AU (2) | AU627465B2 (fr) |
| IL (1) | IL90381A0 (fr) |
| NZ (1) | NZ229297A (fr) |
| PT (1) | PT90731A (fr) |
| WO (1) | WO1991000904A1 (fr) |
| ZA (1) | ZA894137B (fr) |
Families Citing this family (289)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2003794C (fr) * | 1988-12-01 | 2000-02-08 | Hanne R. Johansen | Expression de proteines de vih dans des cellules de drosophiles |
| US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
| US5786464C1 (en) * | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| US6458366B1 (en) | 1995-09-01 | 2002-10-01 | Corixa Corporation | Compounds and methods for diagnosis of tuberculosis |
| US6290969B1 (en) | 1995-09-01 | 2001-09-18 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| US6592877B1 (en) | 1995-09-01 | 2003-07-15 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| US6534312B1 (en) | 1996-02-22 | 2003-03-18 | Merck & Co., Inc. | Vaccines comprising synthetic genes |
| WO1997038087A2 (fr) | 1996-04-05 | 1997-10-16 | Chiron Corporation | Vecteurs a base d'alphavirus de recombinaison, presentant une inhibition reduite de la synthese macromoleculaire cellulaire |
| JP2001500738A (ja) | 1996-09-17 | 2001-01-23 | カイロン コーポレイション | 細胞内疾患を処置するための組成物および方法 |
| US6114148C1 (en) * | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| US6544523B1 (en) | 1996-11-13 | 2003-04-08 | Chiron Corporation | Mutant forms of Fas ligand and uses thereof |
| AU743616B2 (en) * | 1997-02-07 | 2002-01-31 | Merck & Co., Inc. | Synthetic HIV gag genes |
| US6696291B2 (en) | 1997-02-07 | 2004-02-24 | Merck & Co., Inc. | Synthetic HIV gag genes |
| US6261562B1 (en) | 1997-02-25 | 2001-07-17 | Corixa Corporation | Compounds for immunotherapy of prostate cancer and methods for their use |
| ATE376062T1 (de) | 1997-08-04 | 2007-11-15 | Cell Genesys Inc | Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendung |
| US6914131B1 (en) | 1998-10-09 | 2005-07-05 | Chiron S.R.L. | Neisserial antigens |
| CA2308606A1 (fr) | 1997-11-06 | 1999-05-20 | Chiron S.P.A. | Antigenes de neisseria |
| EP1042360A2 (fr) | 1997-12-24 | 2000-10-11 | Corixa Corporation | Composes destines a l'immunotherapie et au diagnostic du cancer du sein, et leur mode d'utilisation |
| ATE446368T1 (de) | 1998-01-14 | 2009-11-15 | Novartis Vaccines & Diagnostic | Antigene aus neisseria meningitidis |
| KR20010041992A (ko) | 1998-03-18 | 2001-05-25 | 길리스 스티브 | 폐암의 치료와 진단을 위한 화합물 및 이를 위한 방법 |
| US20020147143A1 (en) | 1998-03-18 | 2002-10-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| EP2261345A3 (fr) | 1998-05-01 | 2012-01-11 | Novartis Vaccines and Diagnostics, Inc. | Antigènes de Neisseria meningitidis et compositions |
| PL346213A1 (en) | 1998-08-07 | 2002-01-28 | Univ Washington | Immunological herpes simplex virus antigens and methods for use thereof |
| US20030235557A1 (en) | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| EP1121437B1 (fr) | 1998-10-15 | 2008-02-20 | Novartis Vaccines and Diagnostics, Inc. | Genes regules dans les cellules du cancer du sein metastatique et du cancer du colon |
| EP2277893A3 (fr) | 1998-12-08 | 2011-03-30 | Corixa Corporation | Composés et procédés pour le traitement et le diagnostic des infections à chlamydia |
| EP1961813B1 (fr) | 1998-12-16 | 2011-08-10 | Novartis Vaccines and Diagnostics, Inc. | Kinase de type humain dépendant de la cycline (hPNQALRE) |
| US20020119158A1 (en) | 1998-12-17 | 2002-08-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
| US6579973B1 (en) | 1998-12-28 | 2003-06-17 | Corixa Corporation | Compositions for the treatment and diagnosis of breast cancer and methods for their use |
| US7935805B1 (en) | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
| AU2221600A (en) | 1998-12-31 | 2000-07-31 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
| US7393823B1 (en) | 1999-01-20 | 2008-07-01 | Oregon Health And Science University | HER-2 binding antagonists |
| US7625859B1 (en) | 2000-02-16 | 2009-12-01 | Oregon Health & Science University | HER-2 binding antagonists |
| CN1370182A (zh) | 1999-04-02 | 2002-09-18 | 科里克萨有限公司 | 用于治疗和诊断肺癌的化合物和方法 |
| US8143386B2 (en) | 1999-04-07 | 2012-03-27 | Corixa Corporation | Fusion proteins of mycobacterium tuberculosis antigens and their uses |
| RU2245366C2 (ru) | 1999-04-30 | 2005-01-27 | Чирон С.Р.Л. | Антиген neisseria, кодирующая его нуклеиновая кислота, их использование |
| GB9911683D0 (en) | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
| GB9916529D0 (en) | 1999-07-14 | 1999-09-15 | Chiron Spa | Antigenic peptides |
| WO2001024820A1 (fr) | 1999-10-07 | 2001-04-12 | Corixa Corporation | Proteines hybrides de mycobacterium tuberculosis |
| PT2275552E (pt) | 1999-10-29 | 2015-12-07 | Glaxosmithkline Biolog Sa | Péptidos antigénicos de neisseria |
| AU1922101A (en) | 1999-11-18 | 2001-05-30 | Chiron Corporation | Human fgf-21 gene and gene expression products |
| ES2588917T3 (es) | 2000-01-17 | 2016-11-07 | Glaxosmithkline Biologicals Sa | Vacuna de VME suplementada contra meningococo |
| EP1854476A3 (fr) | 2000-02-09 | 2008-05-07 | Bas Medical, Inc. | Utilisation de la relaxine pour traiter des maladies associées à la vasoconstriction |
| WO2001062778A2 (fr) | 2000-02-23 | 2001-08-30 | Smithkline Beecham Biologicals S.A. | Nouveaux composes |
| WO2001062893A2 (fr) | 2000-02-25 | 2001-08-30 | Corixa Corporation | Composes et methodes de diagnostic et d'immunotherapie de la tuberculose |
| EP1261723B1 (fr) | 2000-02-28 | 2008-02-27 | Novartis Vaccines and Diagnostics S.r.l. | Expressions hybrides de proteines de neisseria |
| US20040002068A1 (en) | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| WO2004093810A2 (fr) | 2003-04-21 | 2004-11-04 | Epeius Biotechnologies, Inc. | Methodes et compositions destinees a traiter des troubles |
| JP2003531583A (ja) | 2000-03-08 | 2003-10-28 | カイロン コーポレイション | ヒトｆｇｆ−２３遺伝子および遺伝子発現産物 |
| US20030175700A1 (en) | 2000-04-21 | 2003-09-18 | Ajay Bhatia | Compounds and methods for treatment and diagnosis of chlamydial infection |
| HU230847B1 (en) | 2000-05-19 | 2018-08-28 | Corixa Corp | Prophylactic and therapeutic treatment of infectious and other diseases with mono and disaccharide-based compounds |
| EP1950297A2 (fr) | 2000-05-31 | 2008-07-30 | Novartis Vaccines and Diagnostics, Inc. | Compositions et procédés de traitement de maladie néoplastique utilisant la chimiothérapie et des sensibilisateurs à rayonnement |
| US7700359B2 (en) | 2000-06-02 | 2010-04-20 | Novartis Vaccines And Diagnostics, Inc. | Gene products differentially expressed in cancerous cells |
| EP1370684B1 (fr) | 2000-06-15 | 2008-05-28 | Novartis Vaccines and Diagnostics, Inc. | Polynucleotides lies au cancer du colon |
| EP1542732B1 (fr) | 2000-06-20 | 2009-09-16 | Corixa Corporation | Proteines de fusion du mycobacterium tuberculosis |
| AU2001273149A1 (en) | 2000-06-28 | 2002-01-08 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US7691821B2 (en) | 2001-09-19 | 2010-04-06 | University Of South Florida | Inhibition of SHIP to enhance stem cell harvest and transplantation |
| US20020165192A1 (en) | 2000-09-19 | 2002-11-07 | Kerr William G. | Control of NK cell function and survival by modulation of ship activity |
| MXPA03003690A (es) | 2000-10-27 | 2004-05-05 | Chiron Spa | Acidos nucleicos y proteinas de los grupos a y b de estreptococos. |
| EP1415005B1 (fr) | 2000-12-07 | 2012-11-21 | Novartis Vaccines and Diagnostics, Inc. | Retrovirus endogenes regules positivement dans le cancer de la prostate |
| GB0107658D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
| GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
| WO2002081642A2 (fr) | 2001-04-06 | 2002-10-17 | Georgetown University | Gene brcc-3 et ses utilisations diagnostiques et therapeutiques |
| WO2002081639A2 (fr) | 2001-04-06 | 2002-10-17 | Georgetown University | Gene brcc2 et ses utilisations diagnostiques et therapeutiques |
| AU2002305151A1 (en) | 2001-04-06 | 2002-10-21 | Georgetown University | Gene scc-112 and diagnostic and therapeutic uses thereof |
| CA2446788A1 (fr) | 2001-05-09 | 2002-11-14 | Corixa Corporation | Compositions et procedes pour la therapie et le diagnostic du cancer de la prostate |
| WO2003004657A1 (fr) | 2001-07-05 | 2003-01-16 | Chiron Corporation | Polynucleotides codant pour des polypeptides antigeniques du vih de sous-type b et/ou de sous-type c, polypeptides et leurs utilisations |
| EP2412242A3 (fr) | 2001-07-05 | 2012-06-13 | Novartis Vaccines and Diagnostics, Inc. | Polynucléotides codant pour des polypeptides antigènes de type C du VIH, polypeptides et leurs utilisations |
| ATE466020T1 (de) | 2001-11-09 | 2010-05-15 | Univ Georgetown | Neue isoform des gefässendothelzell wachstumshemmers (vegi) |
| ES2312649T3 (es) | 2001-12-12 | 2009-03-01 | Novartis Vaccines And Diagnostics S.R.L. | Inmunizacion frente a chlamydia trachomatis. |
| DK1581119T3 (da) | 2001-12-17 | 2013-05-13 | Corixa Corp | Sammensætninger og fremgangsmåder til terapi og diagnose af inflammatoriske tarmsygdomme |
| ATE427363T1 (de) | 2002-01-08 | 2009-04-15 | Novartis Vaccines & Diagnostic | In kanzerísen mammazellen differentiell exprimierte genprodukte und ihre verwendungsverfahren |
| US7026465B2 (en) | 2002-02-15 | 2006-04-11 | Corixa Corporation | Fusion proteins of Mycobacterium tuberculosis |
| US7615229B2 (en) | 2002-03-15 | 2009-11-10 | Wyeth Holdings Corporation | Mutants of the P4 protein of nontypable Haemophilus influenzae with reduced enzymatic activity |
| CA2479730A1 (fr) | 2002-03-21 | 2003-10-02 | Sagres Discovery, Inc. | Nouvelles compositions et nouveaux procedes pour le cancer |
| US7244565B2 (en) | 2002-04-10 | 2007-07-17 | Georgetown University | Gene shinc-3 and diagnostic and therapeutic uses thereof |
| US7138512B2 (en) | 2002-04-10 | 2006-11-21 | Georgetown University | Gene SHINC-2 and diagnostic and therapeutic uses thereof |
| US20030206916A1 (en) | 2002-05-03 | 2003-11-06 | Rush-Presbyterian-St. Luke's Medical Center | Immunogenic peptides |
| ATE545651T1 (de) | 2002-06-13 | 2012-03-15 | Novartis Vaccines & Diagnostic | Vektoren zur expression von hml-2-polypeptiden |
| EP2011510B1 (fr) | 2002-07-18 | 2011-01-12 | University of Washington | Compositions pharmaceutiques comportant des fragments de protéine du virus de l'herpès simplex d'acitvité immunologique |
| UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
| PL211654B1 (pl) | 2002-10-08 | 2012-06-29 | Rinat Neuroscience Corp | Przeciwciało skierowane przeciwko NGF do zastosowania w leczeniu bólu pooperacyjnego, zastosowanie tego przeciwciała do wytwarzania leku do leczenia bólu pooperacyjnego i kompozycja farmaceutyczna zawierająca przeciwciało skierowane przeciwko NGF do zastosowania w leczeniu bólu pooperacyjnego |
| AU2003304238A1 (en) | 2002-10-08 | 2005-01-13 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same |
| US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
| SI1575517T1 (sl) | 2002-12-24 | 2012-06-29 | Rinat Neuroscience Corp | Protitelesa proti ĺ˝iväśnemu rastnemu dejavniku in metode njihove uporabe |
| KR101110889B1 (ko) | 2003-01-06 | 2012-02-20 | 코릭사 코포레이션 | 특정의 아미노알킬 글루코사미나이드 포스페이트 화합물 및그들의 용도 |
| US7960522B2 (en) | 2003-01-06 | 2011-06-14 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
| US20040170982A1 (en) | 2003-02-14 | 2004-09-02 | Morris David W. | Novel therapeutic targets in cancer |
| US7767387B2 (en) | 2003-06-13 | 2010-08-03 | Sagres Discovery, Inc. | Therapeutic targets in cancer |
| US20070149449A1 (en) | 2003-02-14 | 2007-06-28 | Morris David W | Therapeutic targets in cancer |
| DE602004030535D1 (de) | 2003-02-19 | 2011-01-27 | Rinat Neuroscience Corp | Verfahren zur behandlung von schmerzen durch verabreichung eines nervenwachstumsfaktor-antagonisten und eines nsaid und diese enthaltende zusammensetzung |
| GB0308198D0 (en) | 2003-04-09 | 2003-05-14 | Chiron Srl | ADP-ribosylating bacterial toxin |
| US20070178066A1 (en) | 2003-04-21 | 2007-08-02 | Hall Frederick L | Pathotropic targeted gene delivery system for cancer and other disorders |
| US7812116B2 (en) | 2003-07-03 | 2010-10-12 | Rush University Medical Center | Immunogenic peptides |
| US7807646B1 (en) | 2003-11-20 | 2010-10-05 | University Of South Florida | SHIP-deficiency to increase megakaryocyte progenitor production |
| US7763592B1 (en) | 2003-11-20 | 2010-07-27 | University Of South Florida | SHIP-deficiency to increase megakaryocyte progenitor production |
| KR20070001932A (ko) | 2003-12-23 | 2007-01-04 | 리나트 뉴로사이언스 코퍼레이션 | 작용물질 항 티알케이씨 항체 및 그의 사용 방법 |
| WO2005093064A1 (fr) | 2004-03-29 | 2005-10-06 | Galpharma Co., Ltd. | Protéine de modification de galectine-9 novatrice et utilisation de celle-ci |
| EP1732949B1 (fr) | 2004-04-07 | 2010-01-27 | Rinat Neuroscience Corp. | Methodes de traitement de la douleur associees au cancer des os par administration d'un antagoniste des facteurs de croissance neuronale |
| EP2199801B1 (fr) | 2004-07-14 | 2013-05-29 | The Regents of The University of California | Biomarqueurs pour la détection précoce du cancer des ovaires |
| US20060024677A1 (en) | 2004-07-20 | 2006-02-02 | Morris David W | Novel therapeutic targets in cancer |
| CA2575663C (fr) | 2004-07-30 | 2013-04-23 | Rinat Neuroscience Corp. | Anticorps anti peptide amyloide beta, et leurs procedes d'utilisation |
| EP1789552A2 (fr) | 2004-08-10 | 2007-05-30 | Institute for Multiple Myeloma and Bone Cancer Research | Procédés pour réguler la différenciation et traiter le myélome multiple |
| BR122016029840B1 (pt) | 2004-09-22 | 2021-10-13 | Glaxosmithkline Biologicals S.A. | Composição imunogênica, método de fabricar uma composição imunogênica, e, uso da composição imunogênica |
| DK1858919T3 (da) | 2005-02-18 | 2012-07-16 | Novartis Vaccines & Diagnostic | Immunogener fra uropathogen Escherichia coli |
| EP1701165A1 (fr) | 2005-03-07 | 2006-09-13 | Johannes Dr. Coy | Utilisation thérapeutique et diagnostique de TKTL1, ses inhibiteurs et ses activateurs |
| BRPI0609547A2 (pt) | 2005-03-31 | 2011-10-18 | Glaxosmithkline Biolog Sa | composição, uso de uma composição, método para o tratamento ou prevenção de infecção por chlamydia, uso de uma ou mais proteìnas de chlamydia, de fragmentos imunogênicos das mesmas ou de polinucleotìdeos codificando os mesmos, método para o tratamento ou prevenção de infecção por chlamydia, e, método para a determinação prévia de infecção por chlamydia em um indivìduo |
| EP1865981A2 (fr) | 2005-04-07 | 2007-12-19 | Chiron Corporation | Cacna1e dans le diagnostic, la detection et le traitement du cancer |
| AU2006235258A1 (en) | 2005-04-07 | 2006-10-19 | Novartis Vaccines And Diagnostics Inc. | Cancer-related genes |
| PE20061323A1 (es) | 2005-04-29 | 2007-02-09 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos |
| PL2426141T3 (pl) | 2005-04-29 | 2015-02-27 | Glaxosmithkline Biologicals Sa | Sposób profilaktyki lub leczenia zakażenia m. tuberculosis |
| JP4997239B2 (ja) | 2005-07-22 | 2012-08-08 | ワイズ・エー・シー株式会社 | 抗ｃｄ２６抗体およびその使用方法 |
| SI3045182T1 (en) | 2005-11-14 | 2018-08-31 | Teva Pharmaceuticals International Gmbh | An antibody to a peptide-associated peptide antagonist to calcitonin for treating a headache in aggregates |
| US20090081157A1 (en) | 2006-01-09 | 2009-03-26 | Richard Syd Kornbluth | Immunostimulatory Combinations for Vaccine Adjuvants |
| EP1981905B1 (fr) | 2006-01-16 | 2016-08-31 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Vaccin contre chlamydia |
| US7935342B2 (en) | 2006-02-02 | 2011-05-03 | Rinat Neuroscience Corp. | Methods for treating obesity by administering a trkB antagonist |
| EP2010226B1 (fr) | 2006-04-07 | 2014-01-15 | The Research Foundation of State University of New York | Polypeptides du récepteur de la transcobalamine, acides nucléiques et modulateurs associés, procédés d'utilisation associés destinés à moduler la croissance cellulaire et à traiter le cancer et la déficience en cobalamine |
| EP2044120B1 (fr) | 2006-06-07 | 2019-01-30 | BioAlliance C.V. | Anticorps reconnaissant un épitope contenant un hydrate de carbone du cd-43 et de l'ace exprimé sur des cellules cancéreuses, et procédés les utilisant |
| WO2008020335A2 (fr) | 2006-06-09 | 2008-02-21 | Novartis Ag | Compositions immunogènes pour streptococcus agalactiae |
| EP2064230A2 (fr) | 2006-08-16 | 2009-06-03 | Novartis AG | Immunogènes pour escherichia coli uropathogène |
| WO2008116116A2 (fr) | 2007-03-20 | 2008-09-25 | Harold Brem | Compositions gm-csf cosméceuticales et leurs procédés d'utilisation |
| EP2170384B1 (fr) | 2007-07-02 | 2016-04-13 | Etubics Corporation | Procédés et compositions de production d'un vecteur adénoviral destiné a être utilisé dans des vaccinations multiples |
| GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
| CA2709135C (fr) | 2007-12-17 | 2018-06-05 | Pfizer Limited | Traitement de la cystite interstitielle |
| ES2550757T3 (es) | 2007-12-18 | 2015-11-12 | Bioalliance C.V. | Anticuerpos que reconocen un epítopo que contiene carbohidratos en CD43 y ACE expresados en células cancerosas y métodos de uso de los mismos |
| EP2274437B1 (fr) | 2008-04-10 | 2015-12-23 | Cell Signaling Technology, Inc. | Compositions et procédés pour la détection des mutations d'egfr en cas de cancer |
| WO2009150623A1 (fr) | 2008-06-13 | 2009-12-17 | Pfizer Inc | Traitement de la prostatite chronique |
| TWI516501B (zh) | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Ｐｃｓｋ９拮抗劑類 |
| CN102224254A (zh) | 2008-09-23 | 2011-10-19 | 哈佛大学校长及研究员协会 | Sirt4及其用途 |
| US9181315B2 (en) | 2009-01-08 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for induced brown fat differentiation |
| WO2010086828A2 (fr) | 2009-02-02 | 2010-08-05 | Rinat Neuroscience Corporation | Anticorps monoclonaux agonistes anti-trkb |
| US8568732B2 (en) | 2009-03-06 | 2013-10-29 | Novartis Ag | Chlamydia antigens |
| US20100297127A1 (en) | 2009-04-08 | 2010-11-25 | Ghilardi Nico P | Use of il-27 antagonists to treat lupus |
| DK2510947T3 (en) | 2009-04-14 | 2016-03-21 | Glaxosmithkline Biolog Sa | Compositions for Immunization against Staphylococcus aureus. |
| WO2010146511A1 (fr) | 2009-06-17 | 2010-12-23 | Pfizer Limited | Traitement d'une vessie hyperactive |
| HRP20141270T1 (xx) | 2009-07-16 | 2015-03-13 | Novartis Ag | Detoksificirani imunogeni escherichie coli |
| WO2011038063A1 (fr) | 2009-09-28 | 2011-03-31 | The Trustees Of The University Of Pennsylvania | Procédé pour diagnostiquer et traiter la cystite interstitielle |
| GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
| AU2011207348A1 (en) | 2010-01-21 | 2012-08-02 | Dana-Farber Cancer Institute, Inc. | Context specific genetic screen platform to aid in gene discovery and target validation |
| UA110103C2 (uk) | 2010-01-27 | 2015-11-25 | Ґлаксосмітклайн Байолоджікалз С.А. | Модифікований туберкульозний антиген |
| AR080291A1 (es) | 2010-02-24 | 2012-03-28 | Rinat Neuroscience Corp | Anticuerpos antagonistas anti receptor de il-7 y procedimientos |
| GB201003333D0 (en) | 2010-02-26 | 2010-04-14 | Novartis Ag | Immunogenic proteins and compositions |
| CN105218674A (zh) | 2010-03-11 | 2016-01-06 | 瑞纳神经科学公司 | 呈pH依赖性抗原结合的抗体 |
| GB201005625D0 (en) | 2010-04-01 | 2010-05-19 | Novartis Ag | Immunogenic proteins and compositions |
| WO2011133931A1 (fr) | 2010-04-22 | 2011-10-27 | Genentech, Inc. | Utilisation d'antagonistes d'il-27 pour traiter une maladie intestinale inflammatoire |
| WO2012015758A2 (fr) | 2010-07-30 | 2012-02-02 | Saint Louis University | Méthodes de traitement de la douleur |
| WO2012064743A2 (fr) | 2010-11-08 | 2012-05-18 | The Johns Hopkins University | Procédés d'amélioration de la fonction cardiaque |
| WO2012072769A1 (fr) | 2010-12-01 | 2012-06-07 | Novartis Ag | Epitopes rrgb de pneumocoque et combinaisons de variantes |
| US9198975B2 (en) | 2010-12-01 | 2015-12-01 | The University Of North Carolina At Chapel Hill | Methods and compositions for targeting sites of neovascular growth |
| US9267112B2 (en) | 2011-05-10 | 2016-02-23 | The Regents Of The University Of California | Adenovirus isolated from Titi Monkeys |
| US10221218B2 (en) | 2011-05-10 | 2019-03-05 | The Regents Of The University Of California | Adenovirus isolated from titi monkeys |
| MX2013013627A (es) | 2011-06-21 | 2014-04-25 | Oncofactor Corp | Composiciones y metodos para la terapia y diagnostico de cancer. |
| US20130071375A1 (en) | 2011-08-22 | 2013-03-21 | Saint Louis University | Compositions and methods for treating inflammation |
| WO2013028527A1 (fr) | 2011-08-23 | 2013-02-28 | Indiana University Research And Technology Corporation | Compositions et procédés pour traiter le cancer |
| AU2012301955A1 (en) | 2011-08-29 | 2014-03-06 | The Regents Of The University Of California | Use of HDL-related molecules to treat and prevent proinflammatory conditions |
| US10093705B2 (en) | 2011-09-13 | 2018-10-09 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for brown fat induction and activity using FNDC5 |
| US10378060B2 (en) | 2011-10-14 | 2019-08-13 | Dana-Farber Cancer Institute, Inc. | ZNF365/ZFP365 biomarker predictive of anti-cancer response |
| CN104053672A (zh) | 2011-11-11 | 2014-09-17 | 瑞纳神经科学公司 | Trop-2特异性抗体及其用途 |
| AU2012356206A1 (en) | 2011-12-22 | 2014-06-26 | Rinat Neuroscience Corp. | Human growth hormone receptor antagonist antibodies and methods of use thereof |
| WO2013093693A1 (fr) | 2011-12-22 | 2013-06-27 | Rinat Neuroscience Corp. | Anticorps spécifiques de staphylococcus aureus et leurs utilisations |
| US8603470B1 (en) | 2012-08-07 | 2013-12-10 | National Cheng Kung University | Use of IL-20 antagonists for treating liver diseases |
| US9605276B2 (en) | 2012-08-24 | 2017-03-28 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
| WO2014072876A1 (fr) | 2012-11-09 | 2014-05-15 | Pfizer Inc. | Anticorps spécifiques du facteur de croissance b dérivé des plaquettes, leurs compositions et leurs utilisations |
| HUE067575T2 (hu) | 2013-03-14 | 2024-10-28 | Genvivo Inc | Javított timidin-kináz gén |
| CN118406688A (zh) | 2013-03-15 | 2024-07-30 | 武田药品工业株式会社 | 抗血浆激肽释放酶抗体 |
| CN105229023B (zh) | 2013-03-15 | 2019-08-16 | 加利福尼亚大学董事会 | 源自线粒体的肽mots3调节代谢和细胞存活 |
| WO2014144844A1 (fr) | 2013-03-15 | 2014-09-18 | The Board Of Trustees Of The Leland Stanford Junior University | Petits arn dérivés d'arnt (arnts) impliqués dans la viabilité cellulaire |
| EP2986717A1 (fr) | 2013-04-19 | 2016-02-24 | The Regents of The University of California | Virus d'amblyomma americanum |
| AU2014264295A1 (en) | 2013-05-07 | 2015-10-29 | Rinat Neuroscience Corp. | Anti-glucagon receptor antibodies and methods of use thereof |
| US10231993B2 (en) | 2013-06-27 | 2019-03-19 | University Of Washington Through Its Center For Commercialization | Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders |
| EP3695841A3 (fr) | 2013-07-01 | 2020-11-04 | The Research Foundation for the State University of New York | Inhibition de ship pour combattre l'obésité |
| US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
| CN113683695A (zh) | 2013-08-02 | 2021-11-23 | 辉瑞公司 | 抗cxcr4抗体及抗体-药物缀合物 |
| RU2708140C1 (ru) | 2013-11-13 | 2019-12-04 | Пфайзер Инк. | Антитела, специфичные в отношении лиганда 1А, подобного фактору некроза опухолей, и их композиции и применения |
| WO2015087187A1 (fr) | 2013-12-10 | 2015-06-18 | Rinat Neuroscience Corp. | Anticorps anti-sclérostine |
| WO2015109212A1 (fr) | 2014-01-17 | 2015-07-23 | Pfizer Inc. | Anticorps anti-il-2 et compositions et utilisations de ceux-ci |
| HUE065397T2 (hu) | 2014-03-21 | 2024-06-28 | Teva Pharmaceuticals Int Gmbh | Kalcitonin génekkel kapcsolatos peptid elleni antagonista antitestek és azokat alkalmazó eljárások |
| AU2015235967B2 (en) | 2014-03-27 | 2020-10-22 | Takeda Pharmaceutical Company Limited | Compositions and methods for treatment of diabetic macular edema |
| WO2015164743A2 (fr) | 2014-04-24 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Suppresseur de tumeur et biomarqueurs oncogènes prédictifs de réponse à un inhibiteur de point de contrôle anti-immunitaire |
| EP3139955B1 (fr) | 2014-04-30 | 2024-03-20 | President and Fellows of Harvard College | Protéines de fusion pour le traitement du cancer et procédés associés |
| US10329556B2 (en) | 2014-05-13 | 2019-06-25 | Bioatla, Llc | Conditionally active biological proteins |
| US10702538B2 (en) | 2014-06-17 | 2020-07-07 | The Research Foundation For The State University Of New York | Ship inhibition to induce activation of natural killer cells |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| ES3034398T3 (en) | 2014-08-28 | 2025-08-18 | Bioatla Inc | Conditionally active chimeric antigen receptors for modified t-cells |
| US10513699B2 (en) | 2014-09-03 | 2019-12-24 | Bioatla, Llc | Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts |
| MX2017003062A (es) | 2014-09-09 | 2017-12-14 | Unum Therapeutics | Receptores quimericos y usos de los mismos en terapia inmune. |
| AU2015328411C1 (en) | 2014-10-06 | 2022-03-03 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
| WO2016057651A1 (fr) | 2014-10-09 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Schéma posologique d'il-2 variables multiples pour le traitement de troubles immunitaires |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| EP4670785A3 (fr) | 2015-01-02 | 2026-04-01 | Takeda Pharmaceutical Company Limited | Anticorps bispécifiques contre la kallicréine plasmatique et le facteur xii |
| HK1248812A1 (zh) | 2015-03-06 | 2018-10-19 | Dana-Farber Cancer Institute, Inc. | 预测在食管胃癌中pd-1通路抑制剂响应的pd-l2生物标记 |
| WO2016154010A1 (fr) | 2015-03-20 | 2016-09-29 | Makidon Paul | Compositions immunogènes pour une utilisation en vaccination contre les bordetella |
| US9758575B2 (en) | 2015-04-06 | 2017-09-12 | Yung Shin Pharmaceutical Industrial Co. Ltd. | Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof |
| PT3283106T (pt) | 2015-04-13 | 2022-02-02 | Pfizer | Anticorpos terapêuticos e as suas utilizações |
| KR20250054123A (ko) | 2015-07-21 | 2025-04-22 | 다케다 파머수티컬 컴패니 리미티드 | Xiia 인자의 단일클론 항체 저해제 |
| US10877045B2 (en) | 2015-07-21 | 2020-12-29 | Saint Louis University | Compositions and methods for diagnosing and treating endometriosis-related infertility |
| WO2017015619A1 (fr) | 2015-07-23 | 2017-01-26 | The Regents Of The University Of California | Anticorps anti-facteur de coagulation xia et leurs utilisations |
| AU2016307967C9 (en) | 2015-08-19 | 2025-02-20 | Pfizer Inc. | Tissue factor pathway inhibitor antibodies and uses thereof |
| WO2017049011A1 (fr) | 2015-09-15 | 2017-03-23 | Scholar Rock, Inc. | Anticorps anti-pro-myostatine/myostatine latente et leurs utilisations |
| WO2017062246A1 (fr) | 2015-10-05 | 2017-04-13 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Souche de rotavirus humain g9p[6] et utilisation comme vaccin |
| WO2017066760A1 (fr) | 2015-10-16 | 2017-04-20 | The Trustees Of Columbia University In The City Of New York | Compositions et méthodes d'inhibition d'antigènes spécifiques à une lignée |
| US11207393B2 (en) | 2015-10-16 | 2021-12-28 | President And Fellows Of Harvard College | Regulatory T cell PD-1 modulation for regulating T cell effector immune responses |
| US10138298B2 (en) | 2015-10-23 | 2018-11-27 | The Regents Of The University Of California | Anti-IL-2 antibodies and compositions and uses thereof |
| WO2017075037A1 (fr) | 2015-10-27 | 2017-05-04 | Scholar Rock, Inc. | Facteurs de croissance amorcés et leurs utilisations |
| CA3002676A1 (fr) | 2015-10-29 | 2017-05-04 | Dana-Farber Cancer Institute, Inc. | Procedes pour identifier, evaluer, prevenir et traiter des troubles metaboliques au moyen de pm20d1 et d'acides amines n-lipides |
| CN106699889A (zh) | 2015-11-18 | 2017-05-24 | 礼进生物医药科技（上海）有限公司 | 抗pd-1抗体及其治疗用途 |
| SG11201805420SA (en) | 2015-12-30 | 2018-07-30 | Kodiak Sciences Inc | Antibodies and conjugates thereof |
| JP2019506398A (ja) | 2016-01-21 | 2019-03-07 | ファイザー・インク | 上皮増殖因子受容体変異体ｉｉｉおよびｃｄ３の単一および二重特異性抗体およびそれらの使用 |
| JP2019512271A (ja) | 2016-03-21 | 2019-05-16 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｔ細胞疲弊状態特異的遺伝子発現調節因子およびその使用 |
| CA3029582A1 (fr) | 2016-07-01 | 2018-01-04 | Research Development Foundation | Elimination de cellules proliferantes de greffons derives de cellules souches |
| EP3515559B1 (fr) | 2016-09-20 | 2025-05-21 | Dana-Farber Cancer Institute, Inc. | Compositions et méthodes pour l'identification, l'évaluation, la prévention et le traitement de la lma au moyen de biomarqueurs usp10 et de modulateurs |
| WO2018080573A1 (fr) | 2016-10-28 | 2018-05-03 | Massachusetts Institute Of Technology | Plate-forme de criblage régulatrice globale crispr/cas |
| WO2018148246A1 (fr) | 2017-02-07 | 2018-08-16 | Massachusetts Institute Of Technology | Procédés et compositions pour circuits génétiques à guidage par arn |
| BR112019017500A2 (pt) | 2017-03-03 | 2020-04-14 | Rinat Neuroscience Corp | anticorpos anti-gitr e métodos de uso dos mesmos |
| JP7177076B2 (ja) | 2017-03-16 | 2022-11-22 | ファイザー・インク | チロシン原栄養性 |
| WO2018191548A2 (fr) | 2017-04-14 | 2018-10-18 | Kodiak Sciences Inc. | Anticorps antagonistes du facteur d du complément et leurs conjugués |
| US11279755B2 (en) | 2017-04-25 | 2022-03-22 | Lbl Biotechnology, Inc. | Use of IL-20 antagonists for treating eye diseases |
| BR112019025243A2 (pt) | 2017-06-02 | 2020-07-14 | Pfizer Inc. | anticorpos específicos para flt3 e usos dos mesmos |
| US11430545B2 (en) | 2017-06-13 | 2022-08-30 | Bostongene Corporation | Systems and methods for generating, visualizing and classifying molecular functional profiles |
| BR112020000679A2 (pt) | 2017-07-13 | 2020-07-14 | Massachusetts Institute Of Technology | visando o complexo hdac2-sp3 para potencializar a função sináptica |
| WO2019016784A1 (fr) | 2017-07-21 | 2019-01-24 | Universidade De Coimbra | Anticorps anti-nucléoline |
| EP4088783A1 (fr) | 2017-08-01 | 2022-11-16 | Ab Studio Inc. | Anticorps bispécifiques et leurs utilisations |
| EP3684421A4 (fr) | 2017-09-18 | 2021-08-04 | Children's Hospital Medical Center | Isolateur fort et ses utilisations dans l'administration de gène |
| JP7155270B2 (ja) | 2017-09-21 | 2022-10-18 | ユーキュア・（ベイジン）・バイオファーマ・カンパニー・リミテッド | 抗ｃｔｌａ４抗体及びその用途 |
| AU2018344859A1 (en) | 2017-10-04 | 2020-04-30 | Hesperix SA | Articles and methods directed to personalized therapy of cancer |
| SG11202003652QA (en) | 2017-10-27 | 2020-05-28 | Univ New York | Anti-galectin-9 antibodies and uses thereof |
| KR102769109B1 (ko) | 2017-11-24 | 2025-02-18 | 유큐(베이징) 바이오파마 코., 엘티디 | 항―ｏｘ４０ 항체 및 그의 용도 |
| EP3746483A1 (fr) | 2018-02-01 | 2020-12-09 | Pfizer Inc | Récepteurs antigéniques chimériques ciblant cd70 |
| WO2019152705A1 (fr) | 2018-02-01 | 2019-08-08 | Pfizer Inc. | Anticorps spécifiques à cd70 et leurs utilisations |
| CA3091352A1 (fr) | 2018-02-21 | 2019-08-29 | The University Of Montana | Composes de trehalose de diaryle et leurs utilisations |
| CA3091502A1 (fr) | 2018-02-23 | 2019-08-29 | Eucure (Beijing) Biopharma Co., Ltd | Anticorps anti-pd-1 et leurs utilisations |
| AU2019227641B2 (en) | 2018-02-28 | 2024-09-26 | Dana-Farber Cancer Institute, Inc. | Methods for treating cancer using combinations of anti-BTNL2 and immune checkpoint blockade agents |
| CN112513070A (zh) | 2018-02-28 | 2021-03-16 | 辉瑞公司 | Il-15变体及其用途 |
| US11572381B2 (en) | 2018-03-02 | 2023-02-07 | The University Of Montana | Immunogenic trehalose compounds and uses thereof |
| CA3092588A1 (fr) | 2018-03-02 | 2019-09-06 | Kodiak Sciences Inc. | Anticorps anti-il-6 et constructions de fusion et conjugues associes |
| CA3091859A1 (fr) | 2018-04-06 | 2019-10-24 | Dana-Farber Cancer Institute, Inc. | Kir3dl3 utile en tant que recepteur hhla2, anticorps anti-hhla2 et leurs utilisations |
| ES2984950T3 (es) | 2018-05-23 | 2024-10-31 | Pfizer | Anticuerpos específicos para CD3 y sus usos |
| CA3100829A1 (fr) | 2018-05-23 | 2019-11-28 | Pfizer Inc. | Anticorps specifiques de gucy2c et leurs utilisations |
| AU2019299439C1 (en) | 2018-07-03 | 2025-06-26 | Sotio Biotech, Inc. | Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof |
| JP7212138B2 (ja) | 2018-07-20 | 2023-01-24 | ヨウキュア（ベイジン）バイオファーマ カンパニー リミテッド | 抗ｃｄ４０抗体及びその使用 |
| MX2021001771A (es) | 2018-08-14 | 2021-07-16 | Sotio Llc | Polipéptidos del receptor de antígeno quimérico en combinación con moléculas del metabolismo trans que modulan el ciclo de krebs y usos terapéuticos de los mismos. |
| AU2019333104B2 (en) | 2018-08-28 | 2026-03-19 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| JP7387743B2 (ja) | 2018-09-12 | 2023-11-28 | ユーカー（ベンジン） バイオファーマ カンパニー，リミテッド | 抗ｔｎｆｒｓｆ９抗体及びその使用 |
| EP3827016B1 (fr) | 2018-10-15 | 2025-12-03 | Elixiron Immunotherapeutics (Hong Kong) Limited | Anticorps dirigés contre le facteur de croissance des granulocytes et des macrophages et leurs utilisations |
| WO2020103885A1 (fr) | 2018-11-19 | 2020-05-28 | Beijing Biocytogen Co., Ltd | Anticorps anti-pd-1 et leurs utilisations |
| AU2019401647A1 (en) | 2018-12-21 | 2021-07-08 | Multitude Inc. | Antibodies specific to MUC18 |
| EP4434541A3 (fr) | 2019-01-23 | 2025-02-26 | New York University | Anticorps spécifiques de la chaîne delta 1 du récepteur des lymphocytes t |
| US12463463B2 (en) | 2019-01-28 | 2025-11-04 | Ab Therapeutics, Inc. | Bispecific antibodies and uses thereof |
| JP7670627B2 (ja) | 2019-02-18 | 2025-04-30 | バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド | ヒト化免疫グロブリン遺伝子座を有する遺伝子改変非ヒト動物 |
| WO2020223121A1 (fr) | 2019-04-30 | 2020-11-05 | Dana-Farber Cancer Institute, Inc. | Méthodes de traitement du cancer à l'aide de combinaisons d'agents anti-cx3cr1 et d'agents de blocage de points de contrôle immunitaires |
| EP3972636A4 (fr) | 2019-05-23 | 2023-08-02 | The University Of Montana | Adjuvants de vaccin à base de ligands du récepteur tlr |
| US12205675B2 (en) | 2019-07-03 | 2025-01-21 | Bostongene Corporation | Techniques for bias correction in sequence data |
| WO2021071830A1 (fr) | 2019-10-07 | 2021-04-15 | University Of Virginia Patent Foundation | Modulation de vaisseaux lymphatiques dans une maladie neurologique |
| AU2020364071A1 (en) | 2019-10-10 | 2022-05-26 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| CA3152623A1 (fr) | 2019-10-11 | 2021-04-15 | Richard D. Cummings | Anticorps anti-tn et leurs utilisations |
| US20230075965A1 (en) | 2020-01-24 | 2023-03-09 | Constantine S. Mitsiades | Uses of biomarkers for improving immunotherapy |
| WO2021151079A1 (fr) | 2020-01-24 | 2021-07-29 | University Of Virginia Patent Foundation | Modulation de vaisseaux lymphatiques dans une maladie neurologique |
| WO2021205325A1 (fr) | 2020-04-08 | 2021-10-14 | Pfizer Inc. | Anticorps anti-gucy2c et leurs utilisations |
| WO2021224850A1 (fr) | 2020-05-06 | 2021-11-11 | Crispr Therapeutics Ag | Peptides masques et anticorps anti-ptk7 masqués les comprenant |
| CA3182925A1 (fr) | 2020-06-02 | 2021-12-09 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Animaux non humains genetiquement modifies ayant un locus d'immunoglobuline a chaine legere |
| WO2021257512A1 (fr) | 2020-06-15 | 2021-12-23 | Academia Sinica | Protéine de fusion ac2-fc humanisée pour le traitement et la prévention d'une infection par sars-cov-2 |
| CN116323668A (zh) | 2020-07-17 | 2023-06-23 | 辉瑞公司 | 治疗性抗体及其用途 |
| US20230287455A1 (en) | 2020-07-30 | 2023-09-14 | Pfizer Inc. | Cells Having Gene Duplications and Uses Thereof |
| US20230374599A1 (en) | 2020-10-19 | 2023-11-23 | Alexander Gusev | Germline biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy |
| WO2022104104A2 (fr) | 2020-11-13 | 2022-05-19 | Dana-Farber Cancer Institute, Inc. | Vaccins à cellules de fusion personnalisés |
| US20240029829A1 (en) | 2020-12-04 | 2024-01-25 | Bostongene Corporation | Hierarchical machine learning techniques for identifying molecular categories from expression data |
| WO2022159793A2 (fr) | 2021-01-25 | 2022-07-28 | Dana-Farber Cancer Institute, Inc. | Procédés et compositions pour identifier un cancer de la prostate neuroendocrinien |
| EP4330969A1 (fr) | 2021-04-29 | 2024-03-06 | BostonGene Corporation | Techniques d'apprentissage machine pour estimer une expression de cellules tumorales dans un tissu tumoral complexe |
| WO2022261183A2 (fr) | 2021-06-08 | 2022-12-15 | Dana-Farber Cancer Institute, Inc. | Compositions et procédés de traitement et/ou d'identification d'un agent pour le traitement de cancers intestinaux |
| US20240327496A1 (en) | 2021-08-02 | 2024-10-03 | Pfizer Inc. | Improved Expression Vectors and Uses Thereof |
| AU2022349103A1 (en) | 2021-09-27 | 2024-03-28 | Sotio Biotech Inc. | Chimeric receptor polypeptides in combination with trans metabolism molecules that re-direct glucose metabolites out of the glycolysis pathway and therapeutic uses thereof |
| EP4433515A1 (fr) | 2021-11-16 | 2024-09-25 | SOTIO Biotech Inc. | Traitement de patients atteints de liposarcome myxoïde/à cellules rondes |
| WO2023097119A2 (fr) | 2021-11-29 | 2023-06-01 | Dana-Farber Cancer Institute, Inc. | Méthodes et compositions pour moduler riok2 |
| CA3249858A1 (fr) | 2022-01-31 | 2023-08-03 | Bostongene Corporation | Techniques d'apprentissage automatique pour cytométrie |
| KR20240139082A (ko) | 2022-02-02 | 2024-09-20 | 화이자 인코포레이티드 | 시스테인 프로토트로피 |
| CA3249166A1 (fr) | 2022-02-16 | 2023-08-24 | The Johns Hopkins University | Procédés de diminution de l'alpha-synucléine pathologique à l'aide d'agents qui modulent fndc5 ou des fragments biologiquement actifs de celui-ci |
| EP4555107B1 (fr) | 2022-07-15 | 2026-03-11 | BostonGene Corporation | Techniques de détection d'une déficience de recombinaison homologue (hrd) |
| WO2024040207A1 (fr) | 2022-08-19 | 2024-02-22 | Sotio Biotech Inc. | Cellules tueuses naturelles (nk) génétiquement modifiées avec des polypeptides récepteurs chimériques en combinaison avec des molécules de trans-métabolisme et leurs utilisations thérapeutiques |
| EP4572787A1 (fr) | 2022-08-19 | 2025-06-25 | SOTIO Biotech Inc. | Cellules immunitaires génétiquement modifiées avec des polypeptides récepteurs chimériques en combinaison avec de multiples molécules du métabolisme trans et leurs utilisations thérapeutiques |
| WO2024215989A1 (fr) | 2023-04-14 | 2024-10-17 | Sotio Biotech Inc. | CELLULES IMMUNITAIRES MODIFIÉES POUR LE TRAITEMENT D'UN CANCER EN COMBINAISON AVEC DES AGONISTES βγ DU RÉCEPTEUR IL-2/IL-15 |
| WO2024215987A1 (fr) | 2023-04-14 | 2024-10-17 | Sotio Biotech Inc. | CELLULES IMMUNITAIRES POUR LE TRAITEMENT DU CANCER EN COMBINAISON AVEC DES CONJUGUÉS IL-15/IL-15Rα |
| WO2025030010A1 (fr) | 2023-08-01 | 2025-02-06 | Vor Biopharma Inc. | Compositions comprenant des cellules souches hématopoïétiques génétiquement modifiées et leurs méthodes d'utilisation |
| WO2025034542A1 (fr) | 2023-08-04 | 2025-02-13 | Cornell University | Panel de signature génique prédisant une réponse cancéreuse à un blocage de point de contrôle immunitaire et radiothérapie |
| WO2025096811A1 (fr) | 2023-10-31 | 2025-05-08 | Bostongene Corporation | Technique d'apprentissage automatique pour identifier des sujets répondant à un inhibiteur de point de contrôle immunitaire (ici) et des sujets n'y répondant pas |
| WO2025165590A1 (fr) | 2024-02-02 | 2025-08-07 | Seven Bridges Genomics Inc. | Techniques de détermination améliorée de charge mutationnelle tumorale (tmb) à l'aide d'une référence génomique spécifique à une population |
| WO2025202359A1 (fr) | 2024-03-27 | 2025-10-02 | Adcendo Aps | Anticorps anti-gpc1 et leurs utilisations |
| WO2025202361A1 (fr) | 2024-03-27 | 2025-10-02 | Adcendo Aps | Anticorps anti-gpc1 et leurs utilisations |
| WO2025223455A1 (fr) | 2024-04-24 | 2025-10-30 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anticorps anti-ptk7/b7h3 et leurs utilisations |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0230222A1 (fr) * | 1986-01-06 | 1987-07-29 | F. Hoffmann-La Roche Ag | Expression du gène gag de HTLV-III |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5931799A (ja) * | 1982-08-16 | 1984-02-20 | Science & Tech Agency | Ｂ型肝炎ウイルス遺伝子を組込んだ組換えプラスミド |
| US4703008A (en) * | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
| GR862412B (en) * | 1985-09-25 | 1987-01-23 | Oncogen | Vaccines and immuinoassays for acquired immune deficiency syndrome |
| WO1988006185A1 (fr) * | 1987-02-11 | 1988-08-25 | Scripps Clinic And Research Foundation | Vecteurs retroviraux d'expression et procedes de production d'antigenes du virus d'hepatite b |
| IL90048A0 (en) * | 1988-04-25 | 1989-12-15 | Merck & Co Inc | Recombinant gag precursor of hiv,its preparation and its use as aids vaccine |
-
1989
- 1989-05-22 AP APAP/P/1989/000126A patent/AP129A/en active
- 1989-05-23 IL IL90381A patent/IL90381A0/xx unknown
- 1989-05-26 NZ NZ229297A patent/NZ229297A/en unknown
- 1989-06-01 ZA ZA894137A patent/ZA894137B/xx unknown
- 1989-06-02 EP EP89870082A patent/EP0345242A3/fr not_active Withdrawn
- 1989-06-02 PT PT90731A patent/PT90731A/pt not_active Application Discontinuation
- 1989-06-30 AU AU37256/89A patent/AU627465B2/en not_active Ceased
- 1989-07-11 AU AU43206/89A patent/AU4320689A/en not_active Abandoned
- 1989-07-11 WO PCT/US1989/002415 patent/WO1991000904A1/fr not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0230222A1 (fr) * | 1986-01-06 | 1987-07-29 | F. Hoffmann-La Roche Ag | Expression du gène gag de HTLV-III |
Non-Patent Citations (1)
| Title |
|---|
| SCIENCE (March 28, 1986) Vol. 231, pp. 1580-1584: * |
Also Published As
| Publication number | Publication date |
|---|---|
| AP8900126A0 (en) | 1989-07-31 |
| AU627465B2 (en) | 1992-08-27 |
| EP0345242A2 (fr) | 1989-12-06 |
| AU3725689A (en) | 1991-01-03 |
| ZA894137B (en) | 1990-06-27 |
| IL90381A0 (en) | 1989-12-15 |
| NZ229297A (en) | 1992-01-29 |
| EP0345242A3 (fr) | 1990-05-30 |
| WO1991000904A1 (fr) | 1991-01-24 |
| PT90731A (pt) | 1989-12-29 |
| AU4320689A (en) | 1991-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP129A (en) | Expression of retrovirus gag protein eukaryotic cells | |
| US5643756A (en) | Fusion glycoproteins | |
| US5580773A (en) | Chimeric immunogenic gag-V3 virus-like particles of the human immunodeficiency virus (HIV) | |
| AU727107B2 (en) | Hiv envelope polypeptides and vaccine | |
| Wagner et al. | Studies on processing, particle formation, and immunogenicity of the HIV-1 gag gene product: a possible component of a HIV vaccine | |
| US6043081A (en) | Expression vectors encoding recombinant proteins comprising a VPR/VPX virion incorporation domain for targeting into HIV-1 or HIV-2 virions | |
| PL161165B1 (pl) | Sposób wytwarzania bialek wirusa AIDS PL | |
| Luo et al. | Expression of gag precursor protein and secretion of virus-like gag particles of HIV-2 from recombinant baculovirus-infected insect cells | |
| WO1994028929A1 (fr) | Polypeptides d'enveloppe du vih | |
| CA2084180A1 (fr) | Expression d'immunogenes specifiques a l'aide d'antigenes viraux | |
| Luo et al. | Chimeric gag-V3 virus-like particles of human immunodeficiency virus induce virus-neutralizing antibodies. | |
| IL102092A (en) | Use of recombinant hiv envelope protein in medicament for treating hiv and therapeutic composition containing the agglomerated protein | |
| EP0577894B1 (fr) | Conception, construction et expression de protéines chimériques pour le développement de vaccins et de réactifs diagnostiques | |
| EP0272858A2 (fr) | Protéines recombinantes d'enveloppe du HIV, produites dans des cellules d'insectes | |
| JPH01500161A (ja) | Ａｉｄｓの原因ウィルスの糖蛋白質、該糖蛋白質の製造方法及びワクチン | |
| CA2155017C (fr) | Fonction proteinique vpr et activite de celle-ci | |
| CA2190972A1 (fr) | Compositions de proteines transactivatrices du virus d'immunodeficience humaine | |
| JP5290576B2 (ja) | 修飾されたｈｉｖ−１エンベロープタンパク質 | |
| JPH0349686A (ja) | レトロウイルスｇａｇ蛋白の真核生物細胞における発現 | |
| JP2002513381A (ja) | ＨＴＬＶ―Ｉ感染およびＨＴＬＶ―ＩＩ感染を予防するためのｅｎｖ―糖タンパク質ワクチン | |
| JP3085704B2 (ja) | ドロソフィラ細胞におけるｈｉｖ蛋白の発現 | |
| US6270959B1 (en) | Human T-cell lymphotropic virus type II envelope protein and human monoclonal antibodies specific therefor | |
| WO1995032000A1 (fr) | Immunogenes de polyproteines de vih | |
| Halsey | Construction and characterization of chimaeric human immunodefiency virus type 1 subtype C Gag virus-like particles | |
| LV10497B (en) | A method for obtaining a vaccine comprising polypeptides derived from the HIV-1 virus envelope gene |